SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees

Abaloparatide (ABL) is a novel, selective activator of the PTH1 receptor signaling pathway. In the 18-month Phase 3 ACTIVE study in women with postmenopausal osteoporosis (NCT01343004), ABL significantly increased bone mineral density (BMD), and decreased the risk of vertebral (VF), nonvertebral (NV...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Endocr Soc
Prif Awduron: Saag, Kenneth, Williams, Setareh, Wang, Yamei, Weiss, Richard, Cauley, Jane
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Endocrine Society 2019
Pynciau:
Bone and Mineral Metabolism
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552091/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-519
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg